Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 9, 2025

Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

NNNicholas J. NeillSSShankha SatpathyKKKarsten Krug

Discussion

Loading...

Member takes

Overview

Integrative analysis reveals PTPN12 drives taxane sensitivity through mitotic defects, suggesting new targets for therapy.

Key Points

  • Identifying tumor vulnerabilities in triple-negative breast cancer is crucial for improving targeted therapy.
  • Inactivation of PTPN12 leads to mitotic defects and increased sensitivity to taxanes in cancer cells.
  • The study utilized proteogenomics and synthetic lethality screening to uncover therapeutic targets.
  • Understanding the role of PTPN12 in chromosomal instability may enhance treatment strategies for TNBC patients.

Cite This Study

Neill et al. (2025) studied this question.

synapsesocial.com/papers/689dfea6d61984b91e13c85ahttps://doi.org/10.1158/2159-8290.cd-23-1173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overexpression of Proteins Involved in Mitotic Progression Underlies High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer2025
  2. 2Unraveling the Complexities in TNBC Gene Interaction Networks Towards Better Therapeutics.2025 · 2 citations
  3. 3Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  4. 4RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress2025
  5. 5Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer2025